Drug intelligence / Profile preview

ASKG222

Development stage: Preclinical
Lead developer: AskGene Pharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

ASKG222 is a fusion protein drug candidate developed by AskGene Pharma using its SmartKine platform. It is designed as an interleukin-2 (IL-2) replacement or inhibitor, targeting the IL-2 pathway to modulate immune responses. The primary therapeutic focus for ASKG222 is the treatment of autoimmune diseases and inflammatory conditions. As of the latest updates, it remains in preclinical development and has not yet entered clinical trials in humans[1][2]. The mechanism involves inhibiting or replacing IL-2 activity to potentially reduce aberrant immune activation associated with autoimmune disorders.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on ASKG222.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKG222.

Explore the full profile